Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q4 2025 Earnings Presentation
12 slides from Phibro Animal Health's earnings presentation, Aug 28, 2025
Slide 1: Financial Results Fiscal Year 2025 Fourth Quarter
Phibro Animal Health Corporation Webcast and Conference Call August 28, 2025 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2025 Fourth Quarter Ended June 30, 2025 August 28, 2025 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or cur
Slide 3: Key Themes
Key Themes Strong Continued Sales Performance in Legacy FY2026 Full Year Performance in Momentum Business Guidance Animal Health Q4 Total Consolidated sales and Q4 Total Animal Health sales Q4 Animal Health Legacy 2026 guidance adjusted EBITDA growth of 39% and adjusted EBITDA growth of Business sal
Slide 4: Financial Performance - Consolidated (Fourth Quarter)
Financial Performance - Consolidated Fourth Quarter, Year-on-Year comparison $ in millions, except per share data Q4 Q4 YOY FY24 FY25 %∆ Consolidated Net Sales $ 273.2 $ 378.7 39% Net Income $ 0.8 $ 17.2 NA Diluted EPS $ 0.02 $ 0.42 NA Adjusted EBITDA $ 33.4 $ 50.0 49% Adjusted Net Income $ 16.7 $ 2
Slide 5: Financial Performance - Consolidated (Full Year)
Financial Performance - Consolidated Full Year, Year-on-Year comparison $ in millions, except per share data Full Year Full Year YOY FY24 FY25 %∆ Consolidated Net Sales $ 1,017.7 $ 1,296.2 27% Net Income $ 2.4 $ 48.3 NA Diluted EPS $ 0.06 $ 1.19 NA Adjusted EBITDA $ 111.2 $ 183.7 65% Adjusted Net In
Slide 6: Financial Performance – Animal Health (Fourth Quarter)
Financial Performance – Animal Health Fourth Quarter, Year-on-Year comparison $ in millions Q4 Q4 FY25 YOY Q4 FY25 Q4 FY25 YOY FY24 Legacy %∆ New MFA Total %∆ Animal Health Net Sales $ 191.5 $ 197.9 3% $ 94.5 $ 292.5 53% MFAs & other 116.7 112.1 (4%) 94.5 206.5 77% Nutritional specialties 42.8 47.2
Slide 7: Financial Performance – Animal Health (Full Year)
Financial Performance – Animal Health Full Year, Year-on-Year comparison $ in millions Full Year Full Year FY25 YOY Full Year FY25 Q4 FY25 YOY FY24 Legacy %∆ New MFA Total %∆ Animal Health Net Sales $ 706.5 $ 754.6 7% $ 208.2 $ 962.8 36% MFAs & other 421.0 438.6 4% 208.2 646.4 54% Nutritional specia
Slide 8: Financial Performance – Other Segments (Fourth Quarter)
Financial Performance – Other Segments Fourth Quarter, Year-on-Year comparison $ in millions Q4 Q4 YOY FY24 FY25 %∆ Mineral Nutrition Net Sales $ 62.1 $ 64.2 3% Adj. EBITDA $ 5.4 $ 5.6 4% Adj. EBITDA Margin 8.7% 8.7% +0 bps Performance Products Net Sales $ 19.6 $ 22.1 13% Adj. EBITDA $ 3.1 $ 3.0 (1%
Slide 9: Financial Performance – Other Segments (Full Year)
Financial Performance – Other Segments Full Year, Year-on-Year comparison $ in millions Full Year Full Year YOY FY24 FY25 %∆ Mineral Nutrition Net Sales $ 243.7 $ 253.2 4% Adj. EBITDA $ 16.4 $ 20.8 27% Adj. EBITDA Margin 6.8% 8.2% +140 bps Performance Products Net Sales $ 67.5 $ 80.2 19% Adj. EBITDA
Slide 10: Key Capitalization Metrics
Key Capitalization Metrics June 30, 2025 Free cash flow was $42 million for the TTM -- positive cash from operating activities Free Cash Flow (1) of $80 million, less capital expenditures of $(38) million. Cash and cash equivalents of $77 million 3.1x gross leverage ratio; $725 million total debt /
Slide 11: Financial Guidance – Phibro Fiscal Year 2026
Financial Guidance – Phibro Fiscal Year 2026 $ in millions, except earnings per share (EPS) data FY 2025 FY 2026 Full Year Guidance Actual Low High Consolidated Net Sales $ 1,296 $ 1,425 $ 1,475 Net Income $ 48 $ 73 $ 83 Diluted EPS $ 1.19 $ 1.79 $ 2.03 Adjusted EBITDA $ 184 $ 225 $ 235 Adjusted Net
Slide 12: Q&A
PAHC Company Overview Q&A 12 August 28, 2025 Webcast and Conference Call